Esperion Therapeutics ESPR Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Esperion Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's cash ratio?
- Esperion Therapeutics (ESPR) reported cash ratio of 0.5× in Q1 2026.
- How has Esperion Therapeutics's cash ratio changed year-over-year?
- Esperion Therapeutics's cash ratio increased by 22.9% year-over-year, from 0.4× to 0.5×.
- What is the long-term trend for Esperion Therapeutics's cash ratio?
- Over 5 years (2020 to 2025), Esperion Therapeutics's cash ratio has grown at a -29.7% compound annual growth rate (CAGR), from 3.2× to 0.6×.
- What does cash ratio mean?
- Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.